治疗药物监测 (Therapeutic Drug Monitoring)
April 2025 - Volume 47 - Issue 2 
https://journals.lww.com/drug-monitoring/pages/currenttoc.aspx

社论（Editorial）
1. 精神药物的治疗药物监测：我们所知道的、不知道的以及争议 (Therapeutic Drug Monitoring of Psychotropic Drugs: What We Know, What We Don't, and the Controversies)。
Spigset, Olav
Therapeutic Drug Monitoring. 47(2):183-184, April 2025.
2. 弥合差距：通过全面实施和评估策略推进药物遗传学检测 (Bridging the Gap: Advancing Pharmacogenetic Testing Through Comprehensive Implementation and Evaluation Strategies)。
Rogers, Sara; Silva, Patrick J.; Ramos, Kenneth
Therapeutic Drug Monitoring. 47(2):185-188, April 2025.

大查房（Grand Round） 
3. 通过治疗药物监测优化囊性纤维化患者的环丙沙星剂量 (Ciprofloxacin Dosage Optimization in Cystic Fibrosis Through Therapeutic Drug Monitoring)。
Sayadi, Hamza; Fromage, Yeleen; Monchaud, Caroline; More
Therapeutic Drug Monitoring. 47(2):189-192, April 2025.
4. 在耐药性癫痫和局灶性癫痫持续状态患者中使用Cobicistat增强咪达唑兰的效果 (Midazolam Boosting With Cobicistat in a Patient With Drug-Resistant Epilepsy and Focal Status Epilepticus)。
van den Born-Bondt, Tessa; Westra, Niels; Krzywicka, Katarzyna; More
Therapeutic Drug Monitoring. 47(2):193-195, April 2025.
5. 误导性肾功能评估导致严重的甲氨蝶呤毒性 (Misleading Renal Function Evaluation Leading to Severe Methotrexate-Induced Toxicity)。
Launay, Manon; Vogrig, Manon; Damin-Pernik, Marlene; More
Therapeutic Drug Monitoring. 47(2):196-198, April 2025.

综述（Review Article）
6. 如何系统性地确定精神药物的治疗参考范围？AGNP的TDM工作组的建议  (How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP)。
Hart, Xenia M.; Amann, Friederike; Baumann, Pierre; More
Therapeutic Drug Monitoring. 47(2):199-210, April 2025.
7. 医院环境中药物遗传学检测的实施和评估策略：范围综述 (Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review)。
Wu, Angela; Raack, Edward J.; Ross, Colin J. D.; More
Therapeutic Drug Monitoring. 47(2):211-247, April 2025.

原创文章（Original Article）
8. 基于模型的日本肺移植患者联合使用他克莫司和伊曲康唑的剂量优化 (Model-Informed Dosing Optimization of Tacrolimus for Concomitant Administration With Itraconazole to Japanese Lung Transplant Recipients)。
Takahashi, Ren; Itohara, Kotaro; Nakagawa, Shunsaku; More
Therapeutic Drug Monitoring. 47(2):248-257, April 2025.
9. 在COVID-19患者中使用Nirmatrelvir/Ritonavir (Paxlovid）的治疗药物监测：一项前瞻性多中心观察性研究的结果 (Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results From a Prospective
Multicenter Observational Study)。
Böger, Corinna R.; Martens-Lobenhoffer, Jens; Worthmann, Hans; More
Therapeutic Drug Monitoring. 47(2):258-264, April 2025.
10. 一种浓度不适用于所有：是时候个性化克罗恩病中英夫利昔单抗的治疗范围了 (One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn Disease)。
Franck, Bénédicte; Tron, Camille; Verdier, Marie-Clémence; More
Therapeutic Drug Monitoring. 47(2):265-273, April 2025.
11. 通过群体药代动力学/药效学模拟优化头孢地尔的剂量：药物成本降低的评估 (Optimizing Cefiderocol Dosing Through Population Pharmacokinetic/Pharmacodynamic Simulation: An Assessment of Drug Cost Reductions)。
Oda, Kazutaka; Jono, Hirofumi; Saito, Hideyuki
Therapeutic Drug Monitoring. 47(2):274-280, April 2025.
12. 在慢性肾病和利尿剂使用背景下解开别嘌醇的暴露-反应关系：对剂量的影响 (Untangling the Exposure–Response Relationship of Allopurinol in the Setting of Chronic Kidney Disease and Diuretic Use: Implications for Dosing)。
Hishe, Hailemichael Z.; Stocker, Sophie L.; Stamp, Lisa K.; More
Therapeutic Drug Monitoring. 47(2):281-288, April 2025.
13. 基于精细群体药代动力学模型的个体化PEG天冬酰胺酶剂量指南用于儿童急性淋巴细胞白血病 (A Refined Population Pharmacokinetic Model–Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic
Leukemia)。
Brigitha, Leiah J.; Zaky, Karen; Pieters, Rob; More
Therapeutic Drug Monitoring. 47(2):289-296, April 2025.
14. 肾功能不全和多病共存的老年日间护理患者的抗抑郁药物血清浓度 (Serum Concentration of Antidepressant Drugs in Geriatric Day Care Patients With Renal Insufficiency and Multimorbidity)。
Reber, Sibylle; Herr, Alexandra S.; Unterecker, Stefan; More
Therapeutic Drug Monitoring. 47(2):297-302, April 2025.

短讯（Short Communication）
15. 伏立康唑和利福布汀联合使用可能增加多重感染患者的不良药物反应风险 (Coadministration of Voriconazole and Rifabutin Can Increase the Risk of Adverse Drug Reactions in Patients With Multiple Infections)。
Kim, Yoonjin; Bae, Sungyeun; Huh, Ki Young; More
Therapeutic Drug Monitoring. 47(2):303-308, April 2025.
16. 多替拉韦联合达芦那韦抗逆转录病毒治疗方案：加倍药物剂量是否总是有用？ (The Case of Dolutegravir Plus Darunavir Antiretroviral Regimens: Is It Always Useful to Double the Drug Doses?)。
Cattaneo, Dario; Ridolfo, Anna Lisa; Giacomelli, Andrea; More
Therapeutic Drug Monitoring. 47(2):309-312, April 2025.

致编辑的信（Letter to the Editor）
17. 验证用于氯氮平剂量预测和治疗药物监测的群体药代动力学模型的挑战 (Challenges in Validating Population Pharmacokinetic Models for Clozapine Dosage Prediction and Therapeutic Drug Monitoring)。
Sherazi, Abdul Wasay
Therapeutic Drug Monitoring. 47(2):313-315, April 2025.